Published in Prostate on October 01, 1998
The L6 protein TM4SF1 is critical for endothelial cell function and tumor angiogenesis. Cancer Res (2009) 1.31
Have we overestimated the benefit of human(ized) antibodies? MAbs (2010) 1.05
TM4SF1: a new vascular therapeutic target in cancer. Angiogenesis (2014) 0.90
Hexa-arginine enhanced uptake and residualization of selective high affinity ligands by Raji lymphoma cells. Mol Cancer (2009) 0.75
Prospective evaluation of cancer clinical trial accrual patterns: identifying potential barriers to enrollment. J Clin Oncol (2001) 6.83
Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group study. J Clin Oncol (1995) 2.26
Use of the polymerase chain reaction for the specific and direct detection of Clostridium difficile in human feces. Rev Infect Dis (1992) 2.10
Prediction of myelotoxicity using semi-quantitative marrow image scores. J Nucl Med (1997) 1.94
Radioassay of yttrium-90 radiation using the radionuclide dose calibrator. J Nucl Med (1997) 1.68
Cisplatin, methotrexate, and vinblastine (CMV): an effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract. A Northern California Oncology Group study. J Clin Oncol (1985) 1.65
Individualized patient education and coaching to improve pain control among cancer outpatients. J Clin Oncol (2001) 1.62
Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-22. J Clin Oncol (1997) 1.56
Clinical assessment of left ventricular regional contraction patterns and ejection fraction by high-resolution gated scintigraphy. J Nucl Med (1975) 1.48
The ventilatory lung scan in the diagnosis of pulmonary embolism. N Engl J Med (1970) 1.44
131I-Lym-1 in mice implanted with human Burkitt's lymphoma (Raji) tumors: loss of tumor specificity due to radiolysis. Cancer Biother Radiopharm (2000) 1.39
The utility of follow-up testing after curative cancer therapy. A critical review and economic analysis. J Gen Intern Med (1997) 1.37
Copper chelates as probes of biological systems: stable copper complexes with a macrocyclic bifunctional chelating agent. Anal Biochem (1985) 1.33
Cardiotoxicity of epirubicin and doxorubicin: assessment by endomyocardial biopsy. Cancer Res (1986) 1.17
Activated ras alleles in human carcinoma of the prostate are rare. Cancer Res (1991) 1.17
Copper-67-labeled monoclonal antibody Lym-1, a potential radiopharmaceutical for cancer therapy: labeling and biodistribution in RAJI tumored mice. J Nucl Med (1988) 1.17
Suramin therapy for patients with symptomatic hormone-refractory prostate cancer: results of a randomized phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone. J Clin Oncol (2000) 1.16
Planar gamma camera imaging and quantitation of yttrium-90 bremsstrahlung. J Nucl Med (1994) 1.15
A study of reproductive function in patients with seminoma treated with radiotherapy and orchidectomy: (SWOG-8711). Southwest Oncology Group. Int J Radiat Oncol Biol Phys (1997) 1.13
NanoFerrite particle based radioimmunonanoparticles: binding affinity and in vivo pharmacokinetics. Bioconjug Chem (2008) 1.11
Increased survival associated with radiolabeled Lym-1 therapy for non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Cancer (1997) 1.11
A comparative study of copper-67 radiolabeling and kinetic stabilities of antibody-macrocycle chelate conjugates. Cancer (1994) 1.09
Potential use of amino acid cocktails to reduce renal tubular reabsorption of radioconjugates. J Nucl Med (1996) 1.08
Maximum-tolerated dose, toxicity, and efficacy of (131)I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphoma. J Clin Oncol (1998) 1.07
Pre-clinical evaluation and efficacy studies of a melanin-binding IgM antibody labeled with 188Re against experimental human metastatic melanoma in nude mice. Cancer Biol Ther (2008) 1.07
Effect of the extent of chelate substitution on the immunoreactivity and biodistribution of 2IT-BAT-Lym-1 immunoconjugates. Cancer Res (1995) 1.06
Synergy of Taxol and radioimmunotherapy with yttrium-90-labeled chimeric L6 antibody: efficacy and toxicity in breast cancer xenografts. Proc Natl Acad Sci U S A (1997) 1.04
Scintigraphy in the diagnosis of osteonecrosis. Clin Orthop Relat Res (1978) 1.02
Review of a 5-year experience with the radiostrontium bone scintiscan. Calif Med (1972) 1.02
Apoptosis-related gene and protein expression in human lymphoma xenografts (Raji) after low dose rate radiation using 67Cu-2IT-BAT-Lym-1 radioimmunotherapy. Cancer Biother Radiopharm (2001) 1.01
Direct dose confirmation of quantitative autoradiography with micro-TLD measurements for radioimmunotherapy. J Nucl Med (1988) 1.01
Serum stability of 67Cu chelates: comparison with 111In and 57Co. Int J Rad Appl Instrum B (1986) 1.00
Characteristics of different phenotypes of polycystic ovary syndrome based on the Rotterdam criteria in a large-scale Chinese population. BJOG (2009) 1.00
Transfer of copper from a chelated 67Cu-antibody conjugate to ceruloplasmin in lymphoma patients. Nucl Med Biol (1999) 0.99
p53 in prostate cancer: frequent expressed transition mutations. J Natl Cancer Inst (1994) 0.99
Yttrium-90-labeled monoclonal antibody for therapy: labeling by a new macrocyclic bifunctional chelating agent. J Nucl Med (1990) 0.97
Low-dose, fractionated radioimmunotherapy for B-cell malignancies using 131I-Lym-1 antibody. Cancer Biother Radiopharm (1998) 0.96
Scintigraphic imaging of a blind-ending ureteral duplication. J Nucl Med (1975) 0.96
Assessment of conventional criteria for the early diagnosis of thrombophlebitis with the 125I-fibrinogen uptake test. Radiology (1977) 0.96
Radioimmunotherapy: recent results and future directions. J Clin Oncol (1996) 0.96
67Cu-versus 131I-labeled Lym-1 antibody: comparative pharmacokinetics and dosimetry in patients with non-Hodgkin's lymphoma. Clin Cancer Res (1999) 0.94
Comparative serum stability of radiochelates for antibody radiopharmaceuticals. J Nucl Med (1987) 0.94
Blood flow in irradiated mouse sarcoma as determined by the clearance of xenon-133. Cancer Res (1972) 0.94
Systemic radiotherapy in metastatic breast cancer using 90Y-linked monoclonal MUC-1 antibodies. Crit Rev Oncol Hematol (2001) 0.94
Vascularity of the femoral head. Tc diphosphonate scintigraphy validated with tetracycline labeling. Clin Orthop Relat Res (1977) 0.94
85 Sr bone scan in neoplastic disease. Semin Nucl Med (1972) 0.93
Macrocyclic chelates of radiometals for diagnosis and therapy. Br J Cancer Suppl (1990) 0.93
Factors affecting 131I-Lym-1 pharmacokinetics and radiation dosimetry in patients with non-Hodgkin's lymphoma and chronic lymphocytic leukemia. J Nucl Med (1999) 0.93
Stable bifunctional chelates of metals used in radiotherapy. Cancer Res (1990) 0.93
Quantitative bremsstrahlung imaging of yttrium-90 using a Wiener filter. Med Phys (1994) 0.92
Urinary prostate specific antigen levels: role in monitoring the response of prostate cancer to therapy. J Urol (1992) 0.92
Cisplatin, doxorubicin, and 5-fluorouracil chemotherapy for salivary gland malignancies: a pilot study of the Northern California Oncology Group. J Clin Oncol (1987) 0.92
Comparative toxicity studies of yttrium-90 MX-DTPA and 2-IT-BAD conjugated monoclonal antibody (BrE-3). Cancer (1994) 0.92
The 85-Sr scintiscan in bone disease. Ann Intern Med (1966) 0.91
Radionuclide assessment of nitroglycerin influence on abnormal left ventricular segmental contraction in patients with coronary heart disease. Circulation (1976) 0.91
p53 abnormalities in primary prostate cancer: single-strand conformation polymorphism analysis of complementary DNA in comparison with genomic DNA. The Cooperative Prostate Network. J Natl Cancer Inst (1997) 0.91
Practical determination of patient-specific marrow dose using radioactivity concentration in blood and body. J Nucl Med (1999) 0.90
A clinical trial of radioimmunotherapy with 67Cu-2IT-BAT-Lym-1 for non-Hodgkin's lymphoma. J Nucl Med (1999) 0.90
Quantitative imaging of mouse L-6 monoclonal antibody in breast cancer patients to develop a therapeutic strategy. Int J Rad Appl Instrum B (1991) 0.90
Antiangiogenic agents and their promising potential in combined therapy. Crit Rev Oncol Hematol (2001) 0.90
A radioimmunoimaging and MIRD dosimetry treatment planning program for radioimmunotherapy. Nucl Med Biol (1996) 0.89
The fate of the bladder in patients with metastatic bladder cancer treated with cisplatin, methotrexate and vinblastine: a Northern California Oncology Group study. J Urol (1985) 0.88
Increased RB1 abnormalities in human primary prostate cancer following combined androgen blockade. Prostate (1998) 0.88
Sodium flux in myotonic muscular dystrophy. Am J Physiol (1968) 0.88
Anti-HLA-DR/anti-DOTA diabody construction in a modular gene design platform: bispecific antibodies for pretargeted radioimmunotherapy. Cancer Biother Radiopharm (2001) 0.88
Hepatic scintiangiographic patterns. Radiology (1974) 0.88
Treatment of B cell malignancies with 131I Lym-1 monoclonal antibodies. Int J Cancer Suppl (1988) 0.87